Display options
Cite
Zheng S, Tasnif Y, Hebert MF, et al. CYP3A5 gene variation influences cyclosporine A metabolite formation and renal cyclosporine disposition. Transplantation. 2013;95(6):821-7doi: 10.1097/TP.0b013e31827e6ad9.
Zheng, S., Tasnif, Y., Hebert, M. F., Davis, C. L., Shitara, Y., Calamia, J. C., Lin, Y. S., Shen, D. D., & Thummel, K. E. (2013). CYP3A5 gene variation influences cyclosporine A metabolite formation and renal cyclosporine disposition. Transplantation, 95(6), 821-7. https://doi.org/10.1097/TP.0b013e31827e6ad9
Zheng, Songmao, et al. "CYP3A5 gene variation influences cyclosporine A metabolite formation and renal cyclosporine disposition." Transplantation vol. 95,6 (2013): 821-7. doi: https://doi.org/10.1097/TP.0b013e31827e6ad9
Zheng S, Tasnif Y, Hebert MF, Davis CL, Shitara Y, Calamia JC, Lin YS, Shen DD, Thummel KE. CYP3A5 gene variation influences cyclosporine A metabolite formation and renal cyclosporine disposition. Transplantation. 2013 Mar 27;95(6):821-7. doi: 10.1097/TP.0b013e31827e6ad9. PMID: 23354298; PMCID: PMC3604156.
Copy Download .nbib Format: NLM
Share it on

Transplantation. 2013 Mar 27;95(6):821-7. doi: 10.1097/TP.0b013e31827e6ad9.

CYP3A5 gene variation influences cyclosporine A metabolite formation and renal cyclosporine disposition.

Transplantation

Songmao Zheng, Yasar Tasnif, Mary F Hebert, Connie L Davis, Yoshihisa Shitara, Justina C Calamia, Yvonne S Lin, Danny D Shen, Kenneth E Thummel

Affiliations

  1. Department of Pharmaceutics, University of Washington, Seattle, WA 98195-7610, USA.

PMID: 23354298 PMCID: PMC3604156 DOI: 10.1097/TP.0b013e31827e6ad9

Abstract

BACKGROUND: Higher concentrations of AM19 and AM1c9, secondary metabolites of cyclosporine A (CsA), have been associated with nephrotoxicity in organ transplant patients. The risk of renal toxicity may depend on the accumulation of CsA and its metabolites in the renal tissue. We evaluated the hypothesis that CYP3A5 genotype, and inferred enzyme expression, affects systemic CsA metabolite exposure and intrarenal CsA accumulation.

METHODS: An oral dose of CsA was administered to 24 healthy volunteers who were selected based on their CYP3A5 genotype. CsA and its six main metabolites in whole blood and urine were measured by liquid chromatography-mass spectometry. In vitro incubations of CsA, AM1, AM9, and AM1c with recombinant CYP3A4 and CYP3A5 were performed to evaluate the formation pathways of AM19 and AM1c9.

RESULTS: The mean CsA oral clearance was similar between CYP3A5 expressors and nonexpressors. However, compared with CYP3A5 nonexpressors, the average blood area under the concentration-time curve (AUC) for AM19 and AM1c9 was 47.4% and 51.3% higher in CYP3A5 expressors (P=0.040 and 0.011, respectively), corresponding to 30% higher AUCmetabolite/AUCCsA ratios for AM19 and AM1c9 in CYP3A5 expressors. The mean apparent urinary CsA clearance based on a 48-hr collection was 20.4% lower in CYP3A5 expressors compared with CYP3A5 nonexpressors (4.2±1.0 and 5.3±1.3 mL/min, respectively; P=0.037), which is suggestive of CYP3A5-dependent intrarenal CsA metabolism.

CONCLUSIONS: At steady state, intrarenal accumulation of CsA and its secondary metabolites should depend on the CYP3A5 genotype of the liver and kidneys. This may contribute to interpatient variability in the risk of CsA-induced nephrotoxicity.

References

  1. Clin Pharmacokinet. 2010 Mar;49(3):141-75 - PubMed
  2. Ther Drug Monit. 2004 Oct;26(5):524-8 - PubMed
  3. Adv Drug Deliv Rev. 1997 Sep 15;27(2-3):201-214 - PubMed
  4. Transplant Proc. 2008 Jun;40(5):1690-5 - PubMed
  5. Clin Pharmacol Ther. 2003 Sep;74(3):245-54 - PubMed
  6. J Am Soc Nephrol. 2005 May;16(5):1501-11 - PubMed
  7. Ther Drug Monit. 1997 Aug;19(4):436-45 - PubMed
  8. Drug Metab Dispos. 1999 Aug;27(8):931-6 - PubMed
  9. Pharmacogenetics. 2003 Nov;13(11):661-74 - PubMed
  10. Biochem Pharmacol. 2004 Nov 1;68(9):1889-902 - PubMed
  11. Clin Pharmacol Ther. 2008 Aug;84(2):248-53 - PubMed
  12. Transplant Proc. 2001 May;33(3):2167-9 - PubMed
  13. Clin Pharmacol Ther. 2004 May;75(5):422-33 - PubMed
  14. Pharmacol Ther. 1993 Feb-Mar;57(2-3):291-345 - PubMed
  15. Mol Pharmacol. 1996 Jul;50(1):52-9 - PubMed
  16. Transplantation. 1992 Mar;53(3):640-5 - PubMed
  17. Transplantation. 2012 Mar 27;93(6):578-9 - PubMed
  18. Transplant Proc. 1988 Apr;20(2 Suppl 2):614-22 - PubMed
  19. Transplant Proc. 2005 May;37(4):1741-4 - PubMed
  20. Transplant Proc. 2005 Jan-Feb;37(1):178-81 - PubMed
  21. J Heart Lung Transplant. 2008 Jul;27(7):741-5 - PubMed
  22. J Appl Physiol (1985). 2003 Sep;95(3):1297-300 - PubMed
  23. N Engl J Med. 2003 Dec 11;349(24):2326-33 - PubMed
  24. Nat Genet. 2001 Apr;27(4):383-91 - PubMed
  25. Clin Pharmacokinet. 2010 Apr;49(4):207-21 - PubMed
  26. Pharmacogenetics. 2003 Nov;13(11):675-82 - PubMed
  27. Lancet. 1981 Feb 28;1(8218):470-1 - PubMed
  28. Pharmacogenomics J. 2008 Dec;8(6):416-22 - PubMed
  29. Clin J Am Soc Nephrol. 2009 Feb;4(2):481-508 - PubMed
  30. Kidney Int. 2006 May;69(10):1858-64 - PubMed
  31. J Heart Lung Transplant. 2011 Mar;30(3):326-31 - PubMed
  32. Lancet. 1978 Dec 23-30;2(8104-5):1323-7 - PubMed
  33. N Engl J Med. 1984 Sep 13;311(11):699-705 - PubMed
  34. Ther Drug Monit. 1990 Nov;12(6):525-32 - PubMed
  35. Pharmacogenetics. 2004 Mar;14(3):147-54 - PubMed
  36. Drug Metab Dispos. 1995 Dec;23(12):1315-24 - PubMed
  37. Mol Pharmacol. 2002 Jul;62(1):162-72 - PubMed
  38. Transplant Proc. 1990 Jun;22(3):1135-6 - PubMed
  39. Clin Pharmacol Ther. 2012 Dec;92(6):737-45 - PubMed
  40. Transplantation. 2004 May 15;77(9):1371-6 - PubMed
  41. Eur J Clin Pharmacol. 1991;41(4):285-90 - PubMed

Substances

MeSH terms

Publication Types

Grant support